No Need to Restrict Hep C DAA Therapy Based on Alcohol Use No Need to Restrict Hep C DAA Therapy Based on Alcohol Use
Alcohol use at any level was not associated with a lower likelihood of responding to direct-acting antiviral therapy for chronic hepatitis C virus infection.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - September 27, 2023 Category: Gastroenterology Tags: Gastroenterology News Source Type: news
Mortality Rates Remain High After Hepatitis C Cure Mortality Rates Remain High After Hepatitis C Cure
Mortality rates remain substantially elevated after successful treatment of hepatitis C infection in the era of interferon-free antiviral therapy, a study of over 20,000 patients has found.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - August 22, 2023 Category: Gastroenterology Tags: Gastroenterology Source Type: news
A Machine Learning Model for Predicting HCC Risk in Chronic HBV A Machine Learning Model for Predicting HCC Risk in Chronic HBV
The authors developed a machine learning algorithm to increase the accuracy of HCC prediction in patients with chronic hepatitis B receiving antiviral therapy.Liver International (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 18, 2023 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
Janssen to Highlight Scientific Advances and Commitment to Transform Cancer Care at ASCO and EHA with More than 90 Presentations Showcasing Robust, Differentiated Portfolio and Pipeline in Hematologic Malignancies and Solid Tumors
This study evaluates an investigational combination regimen of IMBRUVICA® (ibrutinib) plus venetoclax (I+V) for newly diagnosed chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), (Abstracts #7535 and #P617, respectively).Advancing the Science of Solid Tumors Through Precision MedicineJanssen’s continued innovation in solid tumors focuses on advancing precision medicine options for patients with biomarker-driven disease who have limited targeted treatment options and moving patients into earlier lines of therapy when treatments may be more effective. Lung CancerAn oral presentation will report ...
Source: Johnson and Johnson - May 18, 2023 Category: Pharmaceuticals Tags: Innovation Source Type: news
Nasal COVID Treatment Shows Early Promise Against Multiple Variants
An antiviral therapy in early development has the potential to prevent or treat COVID-19 infection when given as a nasal spray in as little as 4 hours before or after exposure. (Source: WebMD Health)
Source: WebMD Health - March 31, 2023 Category: Consumer Health News Source Type: news
Research Uncovers Cheaper Diagnostic Tools For Chronic Hepatitis B in Africa
This study adds guidance as to when such earlier diagnosis may be attained.
“However, research is one thing, health systems strengthening another. Studies like this one add to the impetus and arm the policymakers to make the right decisions,” he says.
But he urges communities to take charge of these findings instead of leaving action in the hands of “sometimes incapacitated policymakers’ hands.”
“The question should be, what is the community saying about findings such as these? If we wait for policymakers to decide when they are going to invest in hepatitis B interventions, we will wait for the rest of our ...
Source: IPS Inter Press Service - Health - March 2, 2023 Category: International Medicine & Public Health Authors: Charles Mpaka Tags: Africa Featured Headlines Health TerraViva United Nations IPS UN Bureau IPS UN Bureau Report Malawi Source Type: news
Janssen Announces Unblinding of Phase 3 CARTITUDE-4 Study of CARVYKTI ® (cilta-cel) as Primary Endpoint Met in Treatment of Patients with Relapsed and Refractory Multiple Myeloma
RARITAN, New Jersey, January 27, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Phase 3 CARTITUDE-4 study evaluating CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) versus pomalidomide, bortezomib, and dexamethasone (PVd) or daratumumab, pomalidomide, and dexamethasone (DPd) for the treatment of patients with relapsed and lenalidomide-refractory multiple myeloma met its primary endpoint of significant improvement in progression-free survival (PFS) at the first pre-specified interim analysis. As a result of meeting the primary endpoint, the Independent Data Monitoring Commi...
Source: Johnson and Johnson - January 27, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Strong Support to Provide DAA Therapy to All Patients With HCV Strong Support to Provide DAA Therapy to All Patients With HCV
Direct-acting antiviral therapy significantly improves liver outcomes, nonliver outcomes, and long-term survival for patients with chronic hepatitis C virus, regardless of disease stage.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - January 11, 2023 Category: Drugs & Pharmacology Tags: Gastroenterology News Source Type: news
Researchers Are Studying Whether Paxlovid Can Treat Long COVID
Months after catching COVID-19 in December 2021, Lavanya Visvabharathy was still testing positive on antigen tests and suffering from symptoms including headaches and intense fatigue. So Visvabharathy, a research assistant professor of neurology at the Northwestern University Feinberg School of Medicine who has studied Long COVID since 2020, decided to conduct an experiment on herself.
She asked her doctor to prescribe her Paxlovid, an antiviral therapy that can treat COVID-19 by inhibiting replication of the virus that causes it. Paxlovid is meant to keep high-risk patients with acute COVID-19 from developing severe disea...
Source: TIME: Health - November 29, 2022 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news
AAP Issues Guidelines to Combat Rise in Respiratory Illness AAP Issues Guidelines to Combat Rise in Respiratory Illness
Recommendations to manage an unprecedented wave of infections include extra doses of antiviral therapy for children at high risk.Medscape Medical News (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - November 21, 2022 Category: Infectious Diseases Tags: Pediatrics News Source Type: news
Janssen to Highlight Latest Scientific Advances in Hematologic Diseases at ASH 2022 with Clinical and Real-World Data Across Innovative Pipeline and Distinguished Portfolio
RARITAN, N.J., November 3, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson are committed to redefining treatment outcomes in the hematology setting and today announced that abstracts from more than 50 company-sponsored studies, plus more than 20 investigator-initiated studies, will be presented at the American Society of Hematology (ASH) Annual Meeting in New Orleans from December 10-13, 2022. Janssen’s commitment to advancing an innovative portfolio of therapies for healthcare professionals and patients is evidenced through more than 70 presentations that span clinical studies and r...
Source: Johnson and Johnson - November 3, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Walgreens, DoorDash, Uber partner on Paxlovid delivery in underserved areas
The collaboration to deliver the oral antiviral therapy for COVID-19 will launch in the coming weeks. (Source: mobihealthnews)
Source: mobihealthnews - October 26, 2022 Category: Information Technology Source Type: news
Antiviral Therapy Improves Survival After Liver Cancer Surgery Antiviral Therapy Improves Survival After Liver Cancer Surgery
The analysis focused on elderly patients after hepatectomy for hepatitis B virus –related hepatocellular carcinoma. The study was published as a preprint and has not yet been peer reviewed.First Look (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 20, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Paxlovid Doesn ’t Work for Healthier Patients, Pfizer Says
Pfizer Inc. plans to stop enrollment in a study of its COVID-19 drug in patients who aren’t at high risk of severe disease after the pill didn’t help alleviate their symptoms, a major setback for broader use of the treatment.
The New York-based drugmaker said Tuesday that it would stop adding new participants to a highly anticipated study testing Paxlovid in a broader population of COVID patients who are at low risk of hospitalization and death. The decision comes after the study failed to demonstrate that the drug reduced COVID symptoms among relatively healthy patients and wasn’t able to show a statisti...
Source: TIME: Health - June 15, 2022 Category: Consumer Health News Authors: Riley Griffin and Madison Muller / Bloomberg Tags: Uncategorized COVID-19 News Desk wire Source Type: news
Longer-term Data from CARTITUDE-1 Study Demonstrate Continued Deep and Durable Responses to CARVYKTI ™ (ciltacabtagene autoleucel) in Heavily Pretreated Patients with Relapsed or Refractory Multiple Myeloma
CHICAGO, ILLINOIS, June 4, 2022 – – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today updated results from the Phase 1b/2 CARTITUDE-1 study evaluating the efficacy and safety of CARVYKTI™ (ciltacabtagene autoleucel; cilta-cel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy. The study included patients with relapsed or refractory multiple myeloma (RRMM) who had received >3 lines of therapy including a proteasome inhibitor (PI), an anti-CD38 monoclonal antibody and an immunomodulatory agent (IMiD) or were double refractory to an IMiD and PI a...
Source: Johnson and Johnson - June 4, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
